Skip to content
drillr.ai
Sign up

01177.HK

Sino Biopharmaceutical Limited

HKSE · Healthcare · Biotechnology · HK

HKD 5.54
−0.98%
Ask drillr

  • Sep 3, 2026, 12:41 UTC

    China Biopharmaceuticals' subsidiary Chia Tai Tianqing received FDA approval for its investigational new drug TQB6426, a GPC3 antibody-drug conjugate for advanced malignant tumors, to proceed with clinical trials.

    Source:

  • Aug 31, 2026, 10:14 UTC

    CIPLA and SBP Group signed an exclusive licensing agreement for the HER2 bispecific antibody-drug conjugate TQB2102.

    Source:

  • Aug 31, 2026, 00:03 UTC

    China Biopharmaceuticals announced Phase I clinical data for its LPA siRNA drug Kylo-11 at the 2026 European Society of Cardiology Congress and in The Lancet.

    Source:

  • Aug 28, 2026, 08:52 UTC

    China Biologic Products' subsidiary Laixinnuo Medical Technology received clinical trial approval from China's NMPA for its innovative drug LM-364 (Nectin-4 TME ADC) for advanced solid tumors, following FDA approval in April and trial initiation in Australia.

    Source:

  • Aug 28, 2026, 00:18 UTC

    China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.

    Source:

  • Aug 23, 2026, 10:05 UTC

    China National Pharmaceutical Group's subsidiary Chia Tai Tianqing received approval from China's National Medical Products Administration Drug Evaluation Center to conduct clinical research for its innovative drug TQF6422 injection (ActRII A/B monoclonal antibody) for weight management in adults with obesity or overweight with comorbidities.

    Source:

  • Aug 21, 2026, 04:31 UTC

    China Biologic Products (01177.HK) shares rose 3.62% to HK$5.585 in morning trading on August 21, 2026, following its earnings release.

    Source:

  • Aug 20, 2026, 06:00 UTC

    Chinese AI startup TranscEngram raised several hundred million yuan in an angel round from investors including SBP Group, PDVC, Zhangjiang Hi-Tech Park, and HON-Flex.

    Source:

  • Aug 20, 2026, 04:01 UTC

    China Biopharmaceutical (01177.HK) reported first-half 2026 results with net profit up 1.4% year-on-year to RMB 3.44 billion, significantly beating market and Citi expectations, and revenue up 10.6% to RMB 19.44 billion, driven by strong innovative drug sales growth of 44.3% to RMB 8.79 billion.

    Source:

  • Aug 19, 2026, 08:51 UTC

    Sino Biopharmaceutical declared an interim dividend of HK$0.07 per share for the six months ended June 2026, up from HK$0.05 in the prior year.

    Source:

  • Aug 19, 2026, 08:51 UTC

    Sino Biopharmaceutical reported interim results for the six months ended June 2026, with revenue of RMB 19.44 billion, up 10.6% year-on-year, and net profit of RMB 3.43 billion, up 1.4%.

    Source:

  • Aug 9, 2026, 11:06 UTC

    China Biologic Products' subsidiary Chia Tai Tianqing received approval from China's National Medical Products Administration for its new drug combination of benmelstobart injection and anlotinib capsules for first-line treatment of advanced squamous non-small cell lung cancer.

    Source:

  • Jul 30, 2026, 08:35 UTC

    China Biologic Products (01177) announced that it will present 21 research results at the 2026 CSCO Annual Meeting, including 5 oral presentations, covering multiple therapeutic areas.

    Source:

  • Jul 10, 2026, 19:44 UTC

    AI² Robotics raised about $735 million in a fresh financing round, pushing its valuation to about $2.8 billion.

    Source:

  • Jul 9, 2026, 06:41 UTC

    Sino Biopharmaceutical announced licensing agreements with GlaxoSmithKline for two approved respiratory products Trelegy and Anoro in China.

    Source:

  • Jul 7, 2026, 22:06 UTC

    China Biologic Pharmaceutical (Sino Biopharmaceutical) entered into an exclusive license agreement with AstraZeneca for TQC3721, granting AstraZeneca exclusive rights outside China, with upfront payment of $200 million and up to $1.9 billion in milestones plus tiered royalties.

    Source:

  • Jul 4, 2026, 11:52 UTC

    Hong Kong-listed companies, led by Tencent Holdings, AIA Group, and Xiaomi Corporation, have conducted share buybacks totaling over 900 billion Hong Kong dollars year-to-date, with June 2026 reaching a monthly record of over 300 billion Hong Kong dollars.

    Source:

  • Jun 12, 2026, 07:26 UTC

    Chia Tai Tianqing and Shionogi's drug Symproic (naldemedine) was approved for marketing in China by the NMPA for opioid-induced constipation.

    Source: